{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-22-000116","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.207863+00:00","generated_at":"2026-06-24T05:54:34.211228+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolus Q2 revenue $37.2M (+42% YoY); reaffirms FY upper-end guidance $143-150M","bullets":["Q2 net revenue $37.2M, up 42% YoY; gross margin 55.4% (adj. 57.4%); operating loss $21.3M.","Reaffirms FY2022 revenue guidance upper end of $143-150M, expects ~50% YoY growth.","Cash $84.5M; expects funding to cash-flow breakeven; Q4 gross margin step-up to 68-71% after royalty end.","European Nuceiva launch on track for Q3 2022; Phase II 'extra strength' Jeuveau enrollment completed.","Added 590 new customer accounts in Q2; total >8,100 purchasing customers; reorder rate >70%."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-22-000116","json":"https://secwatch.observer/filing/0001570562-22-000116.json","markdown":"https://secwatch.observer/filing/0001570562-22-000116.md","text":"https://secwatch.observer/filing/0001570562-22-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000116/0001570562-22-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000116/eols-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:54:34.211228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}